{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T22:07:51Z","timestamp":1789164471062,"version":"build-2803163510"},"reference-count":18,"publisher":"Elsevier BV","issue":"26","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Genocea Biosciences Inc."}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.vaccine.2019.05.009","type":"journal-article","created":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T09:11:10Z","timestamp":1557911470000},"page":"3443-3450","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Therapeutic HSV-2 vaccine decreases recurrent virus shedding and recurrent genital herpes disease"],"prefix":"10.1016","volume":"37","author":[{"given":"David I.","family":"Bernstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7034-7689","authenticated-orcid":false,"given":"Jessica B.","family":"Flechtner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa K.","family":"McNeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4500-5676","authenticated-orcid":false,"given":"Thomas","family":"Heineman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Oliphant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sybil","family":"Tasker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Wald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Hetherington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2019.05.009_b0005","doi-asserted-by":"crossref","first-page":"e114989","DOI":"10.1371\/journal.pone.0114989","article-title":"Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012","volume":"10","author":"Looker","year":"2015","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.vaccine.2019.05.009_b0010","article-title":"Oral antiviral therapy for prevention of genital herpes outbreaks in immunocompetent and nonpregnant patients","author":"Le Cleach","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.vaccine.2019.05.009_b0015","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1517\/14656566.7.6.665","article-title":"Genital herpes: antiviral therapy for symptom relief and prevention of transmission","volume":"7","author":"Gupta","year":"2006","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"10.1016\/j.vaccine.2019.05.009_b0020","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa035144","article-title":"Once-daily valacyclovir to reduce the risk of transmission of genital herpes","volume":"350","author":"Corey","year":"2004","journal-title":"N Engl J Med"},{"issue":"8911","key":"10.1016\/j.vaccine.2019.05.009_b0025","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0140-6736(94)92581-X","article-title":"Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes","volume":"343","author":"Straus","year":"1994","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.vaccine.2019.05.009_b0030","first-page":"235","article-title":"A double-blind study of the efficacy and safety of the ICP10deltaPK vaccine against recurrent genital HSV-2 infections","volume":"70","author":"Casanova","year":"2002","journal-title":"Cutis Cutaneous Med Practitioner"},{"issue":"3","key":"10.1016\/j.vaccine.2019.05.009_b0035","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0264-410X(88)90215-0","article-title":"Placebo-controlled study with subunit herpes simplex virus vaccine in subjects suffering from frequent herpetic recurrences","volume":"6","author":"Kutinova","year":"1988","journal-title":"Vaccine"},{"issue":"47","key":"10.1016\/j.vaccine.2019.05.009_b0040","doi-asserted-by":"crossref","first-page":"8520","DOI":"10.1016\/j.vaccine.2011.09.046","article-title":"Safety and immunogenicity of long HSV-2 peptides complexed with rhHsc70 in HSV-2 seropositive persons","volume":"29","author":"Wald","year":"2011","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2019.05.009_b0045","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.vaccine.2005.08.088","article-title":"A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects","volume":"24","author":"de Bruyn","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.05.009_b0050","article-title":"Identification of novel virus-specific antigens by CD4(+) and CD8(+) T cells from asymptomatic HSV-2 seropositive and seronegative donors. Virology","author":"Long","year":"2014","journal-title":"Epub"},{"issue":"7","key":"10.1016\/j.vaccine.2019.05.009_b0055","doi-asserted-by":"crossref","first-page":"3930","DOI":"10.1128\/JVI.02745-12","article-title":"An adjuvanted herpes simplex virus 2 subunit vaccine elicits a T cell response in mice and is an effective therapeutic vaccine in Guinea pigs","volume":"87","author":"Skoberne","year":"2013","journal-title":"J Virol"},{"issue":"52","key":"10.1016\/j.vaccine.2019.05.009_b0060","doi-asserted-by":"crossref","first-page":"7367","DOI":"10.1016\/j.vaccine.2009.09.044","article-title":"Intramuscular Matrix-M-adjuvanted virosomal H5N1 vaccine induces high frequencies of multifunctional Th1 CD4+ cells and strong antibody responses in mice","volume":"27","author":"Madhun","year":"2009","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2019.05.009_b0065","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1093\/infdis\/jix004","article-title":"Therapeutic vaccine for genital herpes simplex Virus-2 infection: findings from a randomized trial","volume":"215","author":"Bernstein","year":"2017","journal-title":"J Infect Dis"},{"issue":"44","key":"10.1016\/j.vaccine.2019.05.009_b0070","doi-asserted-by":"crossref","first-page":"5314","DOI":"10.1016\/j.vaccine.2016.09.001","article-title":"Immune responses elicited by the GEN-003 candidate HSV-2 therapeutic vaccine in a randomized controlled dose-ranging phase 1\/2a trial","volume":"34","author":"Flechtner","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.05.009_b0075","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiy415","article-title":"Effects of different doses of GEN-003, a therapeutic vaccine for genital HSV-2, on viral shedding and lesions: results of a randomized placebo-controlled","author":"Van Wagoner","year":"2018","journal-title":"Trial J Infec Dis"},{"issue":"9816","key":"10.1016\/j.vaccine.2019.05.009_b0080","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(11)61750-9","article-title":"Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials","volume":"379","author":"Johnston","year":"2012","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.vaccine.2019.05.009_b0085","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1017\/S0950268810002384","article-title":"A clinical specimen collection and transport medium for molecular diagnostic and genomic applications","volume":"139","author":"Daum","year":"2011","journal-title":"Epidemiol Infect"},{"issue":"33","key":"10.1016\/j.vaccine.2019.05.009_b0090","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1016\/j.vaccine.2016.05.033","article-title":"Development of a high-throughput beta-Gal-based neutralization assay for quantitation of herpes simplex virus-neutralizing antibodies in human samples","volume":"34","author":"Baccari","year":"2016","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19306218?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19306218?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:33:13Z","timestamp":1759401193000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19306218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":18,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0264410X19306218"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.05.009","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic HSV-2 vaccine decreases recurrent virus shedding and recurrent genital herpes disease","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}